Nanna joined Novo A/S in 2012.
She spent the first four years with Novo A/S as part of the Seeds team, where she helped build a strong portfolio of seed and Series A stage companies, primarily in Scandinavia. She led the initial investments and served on the Boards of IO Biotech, MinervaX, and Pcovery, and as an Observer with Forendo and Galecto.
Nanna joined the Ventures team in 2016. She now serves on the Boards of Epsilon-3 Bio, Orphazyme and Inventiva.
From 2008-2012, Nanna was an Associate with Apposite Capital, a London-based venture fund, where she was part of the life science investment team and participated in both primary and secondary investments, with multiple portfolio companies leading to highly successful exits for the fund. Earlier in her career, she worked at Cancer Research UK as a research analyst, and as a consultant to various biotech and healthcare venture projects during her MBA.
Nanna received her PhD in Neuroscience from University College London as a Wellcome Trust Scholar. She holds an MBA with distinction from University of Cambridge, where she was a Sainsbury Scholar, and a 1st class BA from University of Oxford.